Implications of rapid virological response in hepatitis C therapy in the US veteran population

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 1, 2012, Pages 105-115

  Hwang, E W ^a,b   Thomas, I C ^a   Cheung, R ^a,b   Backus, L I ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FERRITIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; GENOTYPE; HEPATITIS C; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RAPID VIROLOGICAL RESPONSE; REGISTER; RETROSPECTIVE STUDY; THROMBOCYTE; TREATMENT RESPONSE; UNITED STATES; VETERAN;

ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VETERANS; VIRAL LOAD;

EID: 83555164775     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04903.x     Document Type: Article

References (49)

1. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA,. A sustained virological response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16.
2. Buti M, San Miguel R, Brosa M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639-45.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association of the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatol 2009; 49: 1335-74.
4. Department of Veterans Affairs Hepatitis C Resource Center, Yee HS, Currie SL, Darling JM, Wright TL,. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2006; 101: 2360-78. (Pubitemid 44477566)
5. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65. (Pubitemid 32913521)
6. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
7. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis C Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-71. (Pubitemid 38669209)
8. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ,. Peginterferon alpha-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat 2009; 16: 724-31.
9. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virological response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.e18.
10. Fattovich G, Covolo L, Bibert S, et al. IL-28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162-72.
11. Backus LI, Boothroyd DB, Phillips BR, Mole LA,. Predictors of response of U.S. veterans to treatment for the hepatitis C virus. Hepatol 2007; 46: 37-47. (Pubitemid 47171919)
12. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kD)/ribavirin therapy. Hepatol 2006; 43: 954-60. (Pubitemid 43724620)
13. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC,. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-6.
14. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatol 2008; 47: 1884-93.
15. Ferenci P, Laferl H, Scherzer T-M, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.
16. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S,. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69-75.
17. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)/ribavirin. J Hepatol 2005; 43: 425-33. (Pubitemid 41111423)
18. Poordad F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
19. Jacobson IM, McHutchinson JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
20. Cheung RC, Cunningham BA, Cooper AD,. Effectiveness of a screening program for hepatitis C. Dig Dis Sci 2006; 51: 976-81. (Pubitemid 44030825)
21. Backus LI, Gavrilov S, Loomis TP, et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009; 16: 775-83.
22. Zeuzem S, Heathcote EJ, Shiffman ML, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virological response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003; 39: 106-11. (Pubitemid 36724115)
23. Hwang EW, Thomas IC, Backus LI,. Assessment and Utilization of Rapid Virologic Response to Tailor Treatment Duration in Routine Medical Practice: A Retrospective, Observational, Cohort Study of US Veterans with Chronic Hepatitis C. Chicago, IL: DDW, 2011; Su1018.
24. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatol 2003; 38: 518-526. (Pubitemid 36919874)
25. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatol 2007; 46: 32-36. (Pubitemid 47171918)
26. Mangia A, Minerva M, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatol 2008; 47: 43-50. (Pubitemid 351171040)
27. Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM,. Factors associated with rapid and early virological response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 2010; 17: 139-47.
28. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17. (Pubitemid 41007847)
29. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
30. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatol 2010; 52: 854-63.
31. Harrison SA, Rossaro L, Hu K-Q, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52: 864-74.
32. del Valle J, Mira JA, de los Santos I, et al. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C therapy in HIV/hepatitis C virus coinfected patients. AIDS 2008; 22: 923-30. (Pubitemid 351652242)
33. Gopal K, Johnson TC, Gopal S, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-40. (Pubitemid 44214872)
34. McHutchinson JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of chronic hepatitis C infection. N Engl J Med 2009; 361: 580-93.
35. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138: 108-15.
36. Ascione A, De Luca M, Tataglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-22.
37. Singal AK, Jampana SC, Anand BS,. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dis Dis Sci 2011; 56: 2221-6.
38. Sheth SG, Flamm SL, Gordon FD, Chopra S,. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8. (Pubitemid 29065511)
39. Di Bisceglie Am, Ghalib RH, Hamzeh RM, Rustgi VK,. Early virological response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007; 14: 721-9. (Pubitemid 47414932)
40. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
41. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34. (Pubitemid 47057730)
42. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
43. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
44. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
45. Lange CM, Sarrazin C, Zeuzem S,. Review article: specifically targeted anti-viral therapy for hepatitis C-a new era in therapy. Aliment Pharmacol Ther 2010; 32: 14-28.
46. Campbell MS, Reddy KR,. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther 2004; 20: 249-59. (Pubitemid 39062127)
47. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
48. Suppiah V, Molvodan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
49. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.